Abhijit Banerjee is a Professor in the Department of Economics at the Massachusetts Institute of Technology (MIT). His research focuses on development economics, public health policy, and social protection programs, particularly addressing poverty and inequality in low- and middle-income countries. He has conducted large-scale experiments evaluating interventions such as conditional cash transfers, universal basic income, and healthcare policies. Key areas of interest include the design and implementation of anti-poverty programs, behavioral economics, and the long-term health impacts of infectious diseases like COVID-19. His work often integrates experimental methods to assess policy effectiveness, with contributions to global health studies and economic development strategies. Notably, his research on the RECOVERY trial evaluates treatments for hospitalized COVID-19 patients, while other studies explore financial spillover effects of electronic government transfers in Indonesia and savings behavior interventions in Chile. Banerjee has collaborated on projects analyzing post-COVID-19 health outcomes, labor market dynamics in India, and the role of trusted messengers in public health communication during crises. Despite the breadth of his contributions, specific details about his educational background, grants, or lab affiliations are not explicitly provided in the source text.
Professor Hutan Ashrafian is a clinician-scientist and surgeon at the University of Leeds Business School, holding dual roles as Professor of Research Impact and Senior Research Fellow at Imperial College London. His expertise spans AI in healthcare, metabolic surgery, and ancient history. He pioneered STARD-AI and QUADAS-AI guidelines for AI diagnostics, collaborated on AI-driven breast cancer screening with Google and NHS, and led global health policy initiatives. Ashrafian’s work bridges medicine, history, and philosophy, including his contributions to understanding historical figures’ medical conditions, such as King Tutankhamun’s epilepsy. He has authored over 550 publications, 12 books, and holds a PhD in computational physiology and an MBA with distinction. Awards include the Hunterian Prize and Wellcome Trust Fellowship. His research also explores AI ethics, quantum physics paradoxes, and art-based medical diagnostics. Education: PhD in Computational Physiology (Imperial College London) MBA (Warwick Business School) MD (University College London) Bachelor of Science in Immunology (University College London) Research Interests: Ashrafian’s work spans: AI in Medicine: Diagnostic algorithms, guideline development (STARD-AI/QUADAS-AI), and ethical frameworks. Metabolic Surgery: Bariatric interventions, gut microbiome, and obesity treatments. Ancient History: Medical analyses of historical figures (e.g., Tutankhamun, Julius Caesar) and art-based pathology identification. Philosophy: AI rights (AIONAI law), temporal paradoxes, and the Simulation Argument. Awards: Royal College of Surgeons Arris and Gale Lectureship Hunterian Prize Wellcome Trust Research Fellowship Advising & Innovation: Supervised >50 PhD students, co-founded Oxford Medical Products (weight loss tech), and serves as CSO at Flagship Pioneering’s Preemptive Health division. He advises on NHS digital transformation and global health policy. Labs/Teams: Leads AI initiatives at Imperial’s Institute of Global Health Innovation and collaborates with Google, NICE, and international institutions on health tech solutions.
Dr. Carolyn Emery is a Professor in the Faculty of Kinesiology at the University of Calgary, with joint appointments in Pediatrics and Community Health Sciences at the Cumming School of Medicine. She holds leadership roles as Chair of the Sport Injury Prevention Research Centre (an International Olympic Committee Research Centre) and the Alberta Children’s Hospital Research Institute. Her affiliations include the McCaig Institute for Bone and Joint Health, Hotchkiss Brain Institute, and O’Brien Institute for Public Health. Dr. Emery’s education includes a BScPT from Queen’s University (1988), MSc in Epidemiology from the University of Calgary (1999), and PhD in Epidemiology from the University of Alberta (2004). Her research focuses on injury prevention in youth sports, concussion, and pediatric rehabilitation, aiming to reduce long-term health consequences such as osteoarthritis and post-concussion syndrome. She leads major grants including CIHR’s “SHRed Injuries” and NFL-funded concussion surveillance programs. Her research interests emphasize practical interventions for injury prevention, including neuromuscular training and policy changes. Recent work explores concussion outcomes in adolescents, biomechanical injury mechanisms, and global sport safety initiatives. She has published extensively on topics like sport-related musculoskeletal injuries, concussion management, and the epidemiology of youth sports. Dr. Emery has received over 20 awards, including the Royal Society of Canada Fellowship, Killam Professorship, and CIHR Canada Research Chair. Her work bridges clinical practice, policy, and community engagement to enhance public health outcomes in sports and youth recreation. Her lab, the Sport Injury Prevention Research Centre, collaborates internationally to develop evidence-based strategies for injury prevention. Current projects include evaluating the impact of tackle laws in rugby, head acceleration in wrestling, and long-term consequences of pediatric concussions.
Bobak Mortazavi is an Associate Professor in the Department of Computer Science & Engineering at Texas A&M University. His research focuses on medical analytics, machine learning, wearable sensors, and cyber-physical systems. He leads interdisciplinary projects in healthcare technology, including AI-driven diagnostics and predictive modeling for cardiovascular diseases. He has received notable awards such as the Best Demonstration Award at IEEE EMBS 2012 and the Best Paper Award at the Fourth International Conference on Data Analytics 2015. His work bridges machine learning with clinical applications, emphasizing practical solutions for healthcare challenges. Recent research includes developing AI tools for aortic stenosis detection, electrolyte estimation via ECG, and real-time patient monitoring systems. He collaborates with industry and academic partners to advance telemedicine and wearable health technologies. Key contributions include the SMART-LV project for smartphone-based cardiac diagnostics and the ArterialNet framework for blood pressure reconstruction using wearable sensors. His work is published in top journals like IEEE Journal of Biomedical and Health Informatics and Elsevier's Pervasive and Mobile Computing.
Dr. Camila Aquino serves as Assistant Professor in both the Department of Clinical Neurosciences and Department of Community Health Sciences at the University of Calgary's Cumming School of Medicine, and is a Full Member of the Hotchkiss Brain Institute. As Medical Director of the Deep Brain Stimulation Program, she specializes in Parkinson's disease, essential tremor, dystonia, and chorea management, including EMG-guided botulinum toxin injections. Her educational background includes: M.D. in Medicine from Escola Superior de Ciencias da Santa Casa (2005) M.S. in Neurosciences from Federal University of Sao Paulo (2012) Ph.D. in Neurosciences from Federal University of Sao Paulo (2019) M.S. in Health Research Methods, Clinical Epidemiology from McMaster University (2020) Dr. Aquino's research addresses unmet needs in movement disorders through innovative clinical trial designs for Parkinson's disease, focusing on precision-medicine approaches, early intervention, and outcome optimization. She actively evaluates neuromodulation therapies including Deep Brain Stimulation, Spinal Cord Stimulation, and MRgFUS, with emphasis on expanding indications and improving patient outcomes. As an International Parkinson and Movement Disorder Society member, she chairs the web-based learning committee and serves on evidence-based medicine and outcome measure committees. Analysis of her 15 most recent publications (2021-2025) reveals a cohesive research trajectory centered on Parkinson's disease management, with dominant themes in motor fluctuation treatments, deep brain stimulation methodology, and clinical trial innovation. Her work bridges fundamental clinical practice guidelines with advanced neuromodulation technologies, demonstrating consistent commitment to evidence-based solutions for movement disorders. Her scientific recognition includes: Parkinson Canada research grant Mohammed Al Zaibak Foundation scholarship CAPES scholarship from Brazilian Ministry of Education Dr. Aquino has secured significant research funding supporting clinical trials in Parkinson's disease neuroprotection and neuromodulation therapies. While specific student advisees aren't listed, her leadership of the DBS Program and active clinical trial portfolio indicate substantial mentorship responsibilities. Her grant portfolio emphasizes translational research with direct clinical impact. She directs the University of Calgary's Deep Brain Stimulation Program and contributes to the MRI-guided focused ultrasound initiative. Through her International Parkinson and Movement Disorder Society committee roles, she shapes global educational standards and evidence-based practices in movement disorders.
Professor Maria Craig is a distinguished academic and researcher at the University of New South Wales, Faculty of Medicine & Health, specializing in childhood diabetes research. She holds a prominent position as a Professor with extensive contributions to the field of pediatric endocrinology and diabetes, particularly focusing on type 1 diabetes in children. Professor Craig's educational background includes: MB BS from the University of Melbourne MMedSc(ClinEpid) from the University of Newcastle PhD from the University of Sydney FRACP (Fellow of the Royal Australasian College of Physicians) Professor Craig's research primarily focuses on childhood diabetes, with special emphasis on prediction and prevention of type 1 diabetes. She has a significant interest in the association between viruses and type 1 diabetes, collaborating with the Virology Research Group at Prince of Wales Hospital (POWH). Together with Professor Bill Rawlinson, she leads the viral theme for the multicentre ENDIA study (endia.org.au). As principal investigator for the CoRD trial, she is conducting a world-first phase 1 study using autologous cord blood for prevention of type 1 diabetes in children with islet autoimmunity. Additionally, she serves as principal investigator for the Australasian Diabetes Data Network (ADDN). Her research portfolio also encompasses the epidemiology of various forms of childhood diabetes (type 1, type 2, cystic fibrosis related diabetes and monogenic diabetes) and diabetes complications, in collaboration with Professor Kim Donaghue at the Children's Hospital at Westmead. Professor Craig's extensive publication record, including over 361 journal articles, demonstrates her leadership in advancing our understanding of childhood diabetes. Her recent work shows increasing focus on early detection methods, risk prediction models, technological interventions for diabetes management, and the complex interplay between viral infections and autoimmune diabetes development. She has been instrumental in developing clinical practice guidelines through her role as co-editor of the International Society for Pediatric and Adolescent Diabetes (ISPAD) guidelines. Professor Craig has received numerous prestigious awards recognizing her contributions to pediatric endocrinology and diabetes research: Australian Paediatric Endocrine Group Young Investigator's Award (1997) Asia Pacific Paediatric Endocrine Society Clinical Teaching Award (2008) Lifetime Honorary Member, Caring and Living as Neighbours (2013) Australian Diabetes Society Jeff Flack Diabetes Data Award (2019) Australian Paediatric Endocrine Group Norman Wettenhall Award for Research and Innovation (2019) Throughout her career, Professor Craig has demonstrated exceptional leadership in professional societies, having served as former president/treasurer of the Australasian Paediatric Endocrine Group (APEG) and currently as Scientific Convenor of the Asia Pacific Paediatric Endocrine Society Fellows school. Her work with the ENDIA study and Australasian Diabetes Data Network represents significant collaborative research efforts involving multiple institutions across Australia and internationally. Her principal investigator roles for major studies indicate substantial research funding support. Professor Craig leads several important research initiatives including the ENDIA study, the CoRD trial, and the Australasian Diabetes Data Network. These programs involve multidisciplinary teams of researchers, clinicians, and support staff working collaboratively to advance understanding and treatment of childhood diabetes. Her work at the intersection of virology and diabetes represents a unique and innovative approach to understanding the environmental triggers of type 1 diabetes.
Vincent Quagliarello, MD, is Professor of Medicine in the Department of Infectious Diseases at Yale School of Medicine, where he also serves as Clinical Chief of Infectious Diseases and Vice Chair for Education and Academic Affairs in the Department of Internal Medicine. His research focuses on infections among older adults, with particular expertise in endocarditis, meningitis, and antimicrobial stewardship in geriatric populations. Dr. Quagliarello has been an NIH R01-funded principal investigator studying infections in older adults and received an NIH K07 Academic Leadership Award to mentor postdoctoral trainees and junior faculty. His publication record demonstrates consistent focus on antimicrobial use in elderly patients, particularly those with advanced cancer, nursing home residents, and end-of-life care scenarios. His research has significantly contributed to understanding appropriate antimicrobial therapy in geriatric populations and the management of infections in complex elderly patients. Scientific Awards: Clinical Teacher Award (2011) from Infectious Diseases Society of America Leah Lowenstein Award (2007) from Yale School of Medicine Department of Internal Medicine Teacher of the Year (1998, 1990) Laureate Award (1997) from American College of Physicians (CT Chapter) Bohmfalk Teaching Prize (1997) from Yale School of Medicine Dr. Quagliarello has served as an educational leader at Yale, directing the Internal Medicine Clerkship, the Yale Infectious Diseases Fellowship program, and creating the Department of Medicine Research in Residency Program. His clinical work spans the spectrum of infectious diseases with a special focus on public health impact.
Federica Tomao is an Associate Professor at the Department of Maternal, Child and Urological Sciences within Sapienza University of Rome. She actively teaches and supervises courses in Medicine and Surgery , Nursing , and Midwifery programs across multiple institutions. Current faculty member with academic rank Teaching roles in 6th, 3rd, and 2nd year courses Specialized in gynecologic oncology Research Focus : Her work spans ovarian cancer, breast cancer, and endometrial cancer, emphasizing chemotherapy optimization, precision medicine, and radiomics. Notably, she contributes to understanding PARP inhibitors, immune checkpoint therapies, and fertility preservation techniques in cancer survivors. Recent Publications highlight advancements in sarcopenia analysis, BRCA testing, and radiogenomic nomograms. These studies demonstrate her commitment to bridging imaging and molecular data for improved cancer management. Email : federica.tomao@uniroma1.it
Elena Agapie is an Assistant Professor in the Department of Informatics at the Donald Bren School of Information & Computer Sciences, University of California, Irvine. Her research lies at the intersection of human-computer interaction (HCI), health, and behavior change, focusing on designing technologies that support individuals in adopting and maintaining healthy behaviors through human-centered approaches. She is affiliated with the Connected Learning Lab and the Institute for Future Health at UCI. Her educational background includes a PhD in Human Centered Design and Engineering from the University of Washington, an MS in Computer Science from Harvard University, and a BS in Computer Science from Jacobs University Bremen in Germany. She has also conducted research at Microsoft Research, FXPAL, Intel Labs, and NASA Jet Propulsion Lab. Elena's research focuses on designing tools that integrate evidence-based behavioral interventions with user needs, particularly in mental health, chronic disease management, and social support systems. She explores how technology can support therapist-client collaboration, enable tailored health interventions, and leverage crowd expertise for personalized behavior change plans. Her work often involves participatory design, qualitative studies, and prototyping of interactive systems for diverse populations, including youth, hospitalized patients, and underserved communities. Her recent publications, primarily in top-tier venues like CHI and CSCW, reflect a strong trend toward social computing in health, longitudinal behavior support, and the design of inclusive digital health tools. Key themes include goal setting, conversational agents, social sharing in health tracking, and cross-disciplinary collaboration in health technology development. Best Paper Award (top 1%) at CHI 2017 Honorable Mention Best Paper Award (top 5%) at CHI 2016 Best Paper Award (top 1%) at HCOMP 2015 Honorable Mention Best Paper Award (top 5%) at CHI 2013 Elena has been funded by the National Science Foundation, National Institutes of Health, and UCI internal grants. She actively mentors PhD students including Bruna Oewel, Meeshu Agnihotri, and Mehreen Masood, and is currently recruiting students interested in HCI, health, and behavior change. She previously led the outreach program in the HCDE department at the University of Washington, creating workshops that introduced K–12 students to engineering and human-centered design, reaching over 2,000 students across public schools and community events. She runs initiatives to broaden participation in computing and advises undergraduate students in outreach and curriculum development. Her lab collaborates with clinical partners and interdisciplinary teams to ensure real-world impact of her research.
Dr. Oana Cocarascu is a Senior Lecturer in Artificial Intelligence at the Department of Informatics, Faculty of Natural, Mathematical & Engineering Sciences, King's College London. She holds a PhD and MEng in Computing (Artificial Intelligence) from Imperial College London and conducts applied research focusing on how artificial intelligence can be deployed to support real-world applications, with machine learning and natural language processing as core components of her work. Her research interests span argument mining, explainable AI, machine learning, natural language processing, and symbolic reasoning. She is particularly focused on developing AI systems that can provide transparent, accountable, and ethical decision-making processes. Her work addresses critical challenges in bias mitigation, fairness metrics, fact verification systems, and argumentation-based explanations for complex AI decisions. Analysis of her recent publications (2023-2025) reveals a strong focus on fairness in AI systems, with particular attention to individual fairness metrics and nuanced evaluation frameworks. She has made significant contributions to fact verification systems, especially in multimodal contexts involving charts and tabular data. Her work increasingly integrates argumentation theory with natural language processing to create explainable AI systems that can justify their decisions through structured reasoning. Dr. Cocarascu leads an EPSRC-funded project titled 'A framework for evaluating and explaining the robustness of NLP models' (2024-2027) and is actively involved in the Natural Language Processing Group at KCL. Her research fingerprint shows strong activity in argumentation (100%), decision-making (74%), artificial intelligence (50%), explainable AI (39%), and bias mitigation (35%). She has contributed to numerous high-impact publications in top venues including ACL, EMNLP, AAAI, and the Journal of Artificial Intelligence Research, with a particular focus on making AI systems more transparent, accountable, and aligned with human values. Her work intersects with UN Sustainable Development Goals, particularly those related to reducing inequality and building resilient infrastructure.
Allison Ross Eckard, MD is Professor in the Departments of Pediatrics and Medicine at the Medical University of South Carolina (MUSC) College of Medicine, serving as Division Chief for Pediatric Infectious Diseases and Director of MUSC's Ryan White Pediatric HIV Clinic and HIV Transition Clinic. She maintains an adjunct faculty position at Emory University and holds board certification in Pediatrics and Pediatric Infectious Diseases. Her primary research focuses on metabolic, cardiovascular, and nutritional complications of chronic HIV and antiretroviral therapy across age groups, with emphasis on inflammation's role in comorbidities like cardiovascular disease and bone disorders. Current investigations include NIH R01-funded research on interventions for weight gain and abdominal fat in HIV, vitamin D supplementation, and statin therapy. She has published nearly 60 peer-reviewed papers on HIV pathogenesis and treatment optimization. Dr. Eckard co-chairs the DHHS panel for Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children and serves on the DHHS panel for Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV . Her clinical work specializes in comprehensive HIV care for children through young adults, with particular focus on adolescent/young adult transition issues and global health initiatives through Lespwa Timoun in Haiti. Recent efforts include developing COVID-19 treatment guidelines for children and school safety protocols. HIV Specialist certification (American Academy of HIV Medicine) Fellow, Infectious Diseases Society of America Fellow, Pediatric Infectious Diseases Society Fellow, HIV Medical Association Member, HIV Medical Association's 'Ending the HIV Epidemic' working group She leads MUSC's HIV education initiatives and serves as inpatient consultant for pediatric infectious diseases, with advanced training in tropical medicine. Her NIH-funded research examines targeted interventions to minimize comorbidity development in HIV, while her clinical leadership spans the Ryan White HIV program, transition clinics, and global health partnerships.
Jonathan W. Friedberg, M.D., M.M.Sc. is the Director of the Wilmot Cancer Institute and Professor in the Department of Medicine, Hematology/Oncology at the University of Rochester School of Medicine and Dentistry. He holds the Samuel E. Durand Chair in Medicine and leads one of the nation's premier lymphoma programs. Dr. Friedberg is internationally recognized for his expertise in lymphoma treatment, particularly in developing novel therapies and clinical trial approaches. Dr. Friedberg's research focuses on lymphoma, with particular expertise in Hodgkin lymphoma, non-Hodgkin lymphoma, Waldenstrom macroglobulinemia, and chronic lymphocytic leukemia. His work spans the entire treatment continuum from diagnosis through novel therapies including autologous stem cell transplantation and CAR-T cell interventions. He has built a comprehensive lymphoma program with expertise spanning hematopathology, radiation oncology, dermatology, and neurology, in addition to hematology and medical oncology. His research interests include developing risk-adapted treatment strategies, investigating novel therapeutic agents, and improving outcomes for patients with various lymphoma subtypes. Dr. Friedberg's extensive publication record demonstrates his leadership in lymphoma research, with recent work focusing on immunotherapy combinations, predictive modeling, risk stratification, and novel treatment approaches for various lymphoma subtypes. His research has significantly contributed to the understanding and treatment of lymphomas, particularly in developing more personalized and effective treatment strategies. Scientific Awards: Faculty Academic Mentoring Award (2012) Scholar in Clinical Research (2008) America's Top Doctors Selection (2008) Jacob Gitelman Award (2007) Lawrence A. Kohn Senior Teaching Fellow (2004-2006) Clinical Investigator Career Development Award (2003) Clinical Oncology Research Fellowship "Immunotherapy of Hodgkin's Disease" (2001-2003) Rising stars program for innovative research (2001-2003) As Director of the Wilmot Cancer Institute, Dr. Friedberg leads numerous clinical trials and research initiatives focused on advancing lymphoma treatment. He is actively involved in SWOG and has served in leadership roles for multiple clinical trials investigating novel therapies for lymphoma patients. His practice team includes Anna Morrison, R.N., and Kerri Hugelmaier, N.P., providing comprehensive care for lymphoma patients. Dr. Friedberg has established the Lymphoma Epidemiology of Outcomes (LEO) Consortium, a large observational cohort study supporting broad research on NHL prognosis and survivorship. His leadership extends to national organizations where he contributes to developing clinical practice guidelines and consensus recommendations for lymphoma treatment.
Dr. Samira Lakhal-Littleton is an Associate Professor of Cell Physiology and MRC Senior Non-Clinical Research Fellow at the University of Oxford, affiliated with the Department of Physiology, Anatomy and Genetics and Brasenose College. Her research focuses on iron homeostasis, systems biology, and oxygen sensing mechanisms in cardiovascular and systemic physiology. Education: BSc in Human Genetics (University College London), DPhil in Molecular Medicine (University of Oxford) Her work bridges cell physiology and translational medicine, with key discoveries on hypoxia-inducible factors (HIFs), iron regulatory genes TMPRSS6 and GDF15 , and the role of hepcidin in altitude adaptation and chronic diseases. She utilizes tissue-specific animal models to study iron regulation in heart, kidney, placenta, and vasculature. Recent publications highlight her contributions to understanding: FLASH radiotherapy effects linked to iron-dependent lipid peroxidation Clinical implications of myocardial iron dynamics in heart failure Hepcidin's role in vascular protection and placental iron transfer Biomarker development for predictive iron deficiency diagnostics Scientific Leadership: British Heart Foundation Intermediate Fellowship (2012) MRC Senior Fellowship (2020) BioIron Society Board Member (2019) She collaborates with clinical teams on translational projects and serves as a Tutorial Fellow in Medicine at Brasenose College, mentoring students in physiological sciences.
Karen Piper Hanley is Professor of Molecular Medicine and Head of Division in the Division of Diabetes, Endocrinology & Gastroenterology at the University of Manchester. She serves as the fibrosis lead in the Wellcome Trust Centre for Cell-Matrix Research and previously served as Director of Core Research Technologies (2019-2022). She is also an editorial board member for Scientific Reports. Her research focuses on fibrosis (scarring) mechanisms across multiple organs, particularly liver, kidney, and lung fibrosis. Her lab investigates the cellular and molecular basis of fibrotic disease, with emphasis on how pathological scar components are produced and how they signal to surrounding cells. Key areas include the role of SOX9 transcription factor, integrin beta-1 signaling, Group 1 PAKs, and YAP1 in fibrosis progression. Her recent publications reveal trends toward increased clinical translation of fibrosis research, with studies on health inequalities in liver cancer care, post-COVID diabetes incidence, and innovative approaches to liver disease detection. Her work increasingly integrates spatial transcriptomics and advanced omics technologies to understand cellular transitions in liver disease. Career-track postdoctoral fellowship from the University of Southampton (2006) As senior postgraduate tutor, she has mentored numerous PhD students who have presented at key conferences and authored high-quality manuscripts. All her PhD students have submitted and been awarded their degrees within 4 years. She has successfully guided previous Academic Clinical Fellows to win MRC clinical training fellowships. Her teaching extends to undergraduate Personal & Professional Development and supervision of MRes and BSc students, many of whom have achieved first-class degrees and prestigious awards. Her lab maintains active collaborations with Professor Neil Hanley's group on human development, stem cells, and regenerative medicine, bridging developmental biology with fibrosis research to understand why regeneration is impaired in chronic diseases.
Mark R. Pittelkow is a Professor of Dermatology at the Mayo Clinic, holding a primary appointment as a Consultant in the Department of Dermatology. He completed his MD at Mayo Medical School and advanced training through Mayo Graduate School of Medicine and Northwestern University. His research focuses on cutaneous lymphomas, photoprotection, and skin cancer, with leadership roles in international guidelines (ISCL/EORTC). He contributes to clinical trials, medical education, and interdisciplinary research through affiliations like the Mayo Clinic Comprehensive Cancer Center and Regenerative Biotherapeutics. Education: MD (Mayo Medical School), MS (Biological Sciences, Northwestern), BA (Northwestern University). Research spans cutaneous lymphoma classification, immunology, and translational dermatology. Notable publications address staging systems for mycosis fungoides/Sezary syndrome and photoprotection strategies. His work integrates clinical practice with molecular mechanisms, such as JAK inhibitor responses in lichen planus. Labs/Teams: Collaborates with Mayo Clinic Cancer Center and interdisciplinary groups in immunotherapy and regenerative medicine. Supervises clinical trials and postdoctoral training programs.
